Literature DB >> 31360028

Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy.

Lise L Gluud1, Rebecca Jeyaraj2, Marsha Y Morgan2.   

Abstract

Randomised clinical trials and systematic reviews of research findings can provide high-quality evidence for decision-making in the management of patients with hepatic encephalopathy. A large number of clinical trials have been undertaken, over the last 50 years, relative to the prevention and treatment of this condition. However, changes have been made, during this time, in the classification of hepatic encephalopathy, diagnostic criteria and assessment measures. These temporally based changes and the consequent lack of standardisation make it difficult to compare interventions and to evaluate their comparative efficacy and safety. While some consensus has been reached in relation to the diagnostic evaluation, classification and monitoring of patients in clinical trials, there is less surety about the choice of clinical endpoints. These outcome measures should be universally applicable, easily measured and clinically relevant. This article reviews the current recommendations regarding outcome selection and outlines some of the potential problems and pitfalls inherent in clinical trial evaluating interventions for the management of hepatic encephalopathy.

Entities:  

Keywords:  CFF, Critical Flicker Fusion Frequency; EEG, Electroencephalogram; EQ-5D, European Quality of Life-5 Dimensions; ICMJE, International Committee of Medical Journal Editors; ICT, Inhibitory Control Test; ICTRP, International Clinical Trials Registry Platform; PHES, Psychometric Hepatic Encephalopathy Score; WHO, World Health Organisation; cirrhosis; mortality; risk-benefit; serious adverse events; surrogate markers

Year:  2019        PMID: 31360028      PMCID: PMC6637116          DOI: 10.1016/j.jceh.2019.02.004

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  70 in total

Review 1.  Neuropsychological characterization of hepatic encephalopathy.

Authors:  K Weissenborn; J C Ennen; H Schomerus; N Rückert; H Hecker
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

2.  Critical flicker frequency for quantification of low-grade hepatic encephalopathy.

Authors:  Gerald Kircheis; Matthias Wettstein; Lars Timmermann; Alfons Schnitzler; Dieter Häussinger
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

3.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

4.  The electroencephalograph in liver disease.

Authors:  B G PARSONS-SMITH; W H SUMMERSKILL; A M DAWSON; S SHERLOCK
Journal:  Lancet       Date:  1957-11-02       Impact factor: 79.321

5.  Neuropsychological aspects of portal-systemic encephalopathy.

Authors:  H Schomerus; W Hamster
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

6.  Prognostic significance of hepatic encephalopathy in patients with cirrhosis.

Authors:  J Bustamante; A Rimola; P J Ventura; M Navasa; I Cirera; V Reggiardo; J Rodés
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

7.  Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.

Authors:  H O Conn; C M Leevy; Z R Vlahcevic; J B Rodgers; W C Maddrey; L Seeff; L L Levy
Journal:  Gastroenterology       Date:  1977-04       Impact factor: 22.682

8.  Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease.

Authors:  Z M Younossi; G Guyatt; M Kiwi; N Boparai; D King
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

9.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

10.  Evidence-based medicine: useful tools for decision making.

Authors:  J C Craig; L M Irwig; M R Stockler
Journal:  Med J Aust       Date:  2001-03-05       Impact factor: 7.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.